echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The first subcutaneous injection: Roche's Alzheimer's disease drug received FDA breakthrough therapy designation

    The first subcutaneous injection: Roche's Alzheimer's disease drug received FDA breakthrough therapy designation

    • Last Update: 2021-10-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On October 8, Roche announced that Gantenerumab, an anti-amyloid beta antibody administered subcutaneously, has been approved by the U.


    From: Roche official website

    This qualification is based on the SCarlet RoAD and Marguerite RoAD trials and other studies where Gantenerumab significantly reduced amyloid plaque deposits in the brain


    Roche stated that Gantenerumab has the potential for home delivery as the first subcutaneous AD therapy currently under development to enter the late clinical stage


    Roche stated that Gantenerumab has the potential for home delivery as the first subcutaneous AD therapy currently under development to enter the late clinical stage


    AD is a progressive and fatal brain disease characterized by decreased memory, language, and other thinking abilities, as well as changes in mood and behavior


    In June of this year, the FDA took the lead in accelerating the approval of Bojian’s Aducanumab based on biomarkers


    In September, Eisai/Bojian submitted the BLA of its new Alzheimer's disease drug Lecanemab (BAN2401) to the FDA on a rolling basis, firing the first shot in the AD competition after Aducanumab


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.